Antibody-conjugated carriers such as HER2-targeted polymeric nanoparticles loaded with paclitaxel precursor phytochemicals have shown improved selectivity and cytotoxicity in breast cancer models [98]. Here, ERBB2 is linked to breast carcinoma.